MeiraGTx’s gene therapy for Parkinson’s disease will enter Phase 3 testing under a new joint venture the biotech is forming with Hologen, a generative AI startup. The joint venture has up to $230 million in committed capital; MeiraGTx gets additional cash for its pipeline.
Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA twice turned back applications for the drug/device combination product.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
Cala Health closed a $50 million funding round. The Silicon Valley-based company sells an FDA-cleared wearable device that temporarily relieves hand tremors in people with essential tremor and Parkinson’s disease.
In addition to meeting the main safety and tolerability goal, MieraGTx Holdings’ gene therapy for Parkinson's disease also showed signs of efficacy. The one-time treatment is intended to reprogram dysfunctional brain circuits.
Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing.
The bi-partisan passage during an election year of the End Parkinson’s Act shows that addressing a healthcare crisis, especially in our senior population, may be one of the few remaining issues that transcend party lines.
Help shape the future of healthcare benefits by sharing your insights.
Routine NM-MRI for individuals at risk of Parkinson's could provide a means of identifying the disease before symptoms emerge.
Cerevel Therapeutics drug tavapadon met the main and secondary goals of a pivotal Parkinson’s disease clinical trial. That drug and others will join the neuroscience portfolio of AbbVie, which is in the process of acquiring Cerevel.
Merck’s acquisition of Caraway Therapeutics adds programs for genetically defined neurodegenerative diseases. One of those programs addresses a target that was the focus of a different startup purchased by Merck in 2019.
A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Cala Health recently launched its kIQ system — which it calls the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with essential tremor and Parkinson’s disease.
An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”
Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $4.2 billion in milestone payments.
PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator is accepting applications for the next group of startups for the fall program. The theme is innovations in real-world evidence.
Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.